100 Pine Street
Suite 500
San Francisco, CA 94111
United States
415-512-7740
https://www.adynxx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Richard Orr Esq., J.D. | President, CEO, Principal Financial Officer & Director | 473.59k | N/A | 1961 |
Dr. Julien Mamet Ph.D. | Founder, Chief Scientific Officer & Director | 378.47k | N/A | 1976 |
Mr. William Martin | Executive Vice President of Corporate Development & Operations | N/A | N/A | N/A |
Ms. Dina Gonzalez | Principal Accounting Officer & Senior VP of Finance | N/A | N/A | N/A |
Ms. Kimberley Hebert | Senior Director of Clinical Operations | N/A | N/A | N/A |
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
Adynxx, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.